MHC class II molecules on graft endothelium promote acute rejection

A limitation of organ transplant is acute rejection of the graft by the host immune system. Graft rejection is mediated by the development of CD8+ cytotoxic T cells that target donor MHC class I molecules, and in animal models, these cells have been shown to develop in secondary lymphoid organs. However, in humans, there is evidence that cytotoxic T cells mature within the graft without trafficking to secondary sites.

A new study in the inaugural issue of JCI Insight indicates that the development of graft-targeting CD8+ cytotoxic T cells requires CD4+ effector memory T cells. Specifically, Jordan Pober and colleagues at Yale University used a mouse model in which human artery segments are grafted into immunodeficient mice followed by adoptive transfer of human T cells that are allogenic to the graft.

Using this model, the researchers determined that CD4+ effector memory T cells are activated by MHC class II molecules on graft endothelial cells and promote development of graft-targeting CD8+ cytotoxic T cells. Moreover, eliminating class II MHC expression on endothelial cells prevented CD8+ T effector memory cell responses.

The results of this study indicate that blocking interactions between CD4+ effector memory T cells and class II MHC molecules should be further explored as a potential intervention to limit .


Explore further

Engineered cytomegalovirus protects monkeys from HIV equivalent

More information: Parwiz Abrahimi et al. Blocking MHC class II on human endothelium mitigates acute rejection, JCI Insight (2016). DOI: 10.1172/jci.insight.85293
Citation: MHC class II molecules on graft endothelium promote acute rejection (2016, January 21) retrieved 20 June 2019 from https://medicalxpress.com/news/2016-01-mhc-class-ii-molecules-graft.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more